Clinical Trial Design & Drug Safety

← Back to Domain-Specific Families

Abstractions about how clinical research and drug therapy are structured and evaluated, including trial design and validity concepts (clinical study design, assay sensitivity, carryover effect, clinical-trial stratification), and categories of medication-related harm and safety (adverse drug reaction, medication error, polypharmacy, therapeutic duplication).

22 abstractions in this family — domain-specific abstractions that sit near one another in structural-signature space (k-means over structural-signature embeddings). Each is shown with its short description.

• Adverse Drug Event — Harm to a patient caused by the pharmacology of a drug rather than the process of delivering it — bracketing mechanistically unlike injuries under one causal structure so the prescribing question becomes a benefit-to-harm ratio, not a binary safety verdict.
• Adverse Drug Reaction — Classify an unintended, harmful response arising under correct drug use — not through any administration error — by an ABCDEF taxonomy whose pivotal dose-related-versus-idiosyncratic split reads off predictability, remedy, and whether trials could ever have caught it.
• Assay sensitivity — A clinical trial's ability to distinguish an effective intervention from a less effective or ineffective one, inferred from design, conduct, endpoints, and internal or historical evidence rather than from a null result alone.
• Carryover Effect — The validity threat in crossover and within-subject designs where residual influence from an earlier treatment persists into a later measurement window, biasing the contrast — its magnitude set by the unit's relaxation time against the inter-treatment gap.
• Charlson Comorbidity Index — The Charlson Comorbidity Index assigns weighted points to specified coexisting conditions and combines them into a prognostic score associated with mortality or survival risk over a declared time horizon.
• Clinical Study Design — The architecture that connects a human clinical question to a target population, interventional or observational exposure structure, timing, measurement, bias control, and analysis under ethical and practical constraints.
• Clinical Trial — A prospective, protocol-governed study in human participants that deliberately evaluates a biomedical or behavioral intervention through prespecified health outcomes under ethical and scientific oversight.
• Clinical-Trial Stratification — The prespecified partitioning of trial participants or results by a non-treatment factor so important subgroups are balanced, represented, or analyzed separately to reduce confounding and clarify treatment comparisons.
• Combination therapy — Combination therapy or polytherapy is therapy that uses more than one medication or modality.
• Contraindication — Flag the sparse patient conditions under which a normally-indicated treatment becomes inadvisable, by naming the specific context in which its risk-benefit balance flips sign.
• Functional Cure (Chronic Viral Infection) — Recognize sustained disease-specific control of a chronic viral infection without claiming that every persistent viral source has been eliminated.
• Idiosyncratic Reaction — Classify a rare drug harm as a distinct causal category — dose-independent, qualitatively different in kind, and confined to a small biologically-defined susceptible tail — so it is understood not as too-much-drug but as uniform exposure meeting a heterogeneous responder population.
• Lipinski's Rule of Five — Flag possible oral absorption or permeation difficulty from four empirical molecular-property thresholds, without treating the alert as a verdict.
• Medication Error — Any preventable deviation in the medication-use pipeline that could expose a patient to unintended pharmacologic action, whether or not harm results — a defence-in-depth failure whose harm rate is the product of escape probabilities across every stage, so leverage lies in downstream catch rates, not upstream error counts.
• Obesity paradox — The counterintuitive observational association, reported in some disease-selected populations, between higher body-mass categories and lower mortality, whose apparent protective reading competes with confounding, reverse causality, selection, measurement, and treatment explanations.
• Polypharmacy — Shift the unit of clinical attention from the single prescription to the whole regimen, sorting the combined risk of concurrent drugs into three channels — pharmacokinetic collisions, pharmacodynamic summation, and the prescribing cascade — under one appropriate-versus-problematic binary.
• Prototype Drug — Use a well-characterized member of a pharmacologic class as the comparison exemplar from which the class's shared actions, differences, cautions, and later members are taught or evaluated.
• Provocation test — A test that deliberately exposes a participant to a suspected trigger, control, or stressor and observes the response.
• Surrogate Endpoint — In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship.
• Surrogate Endpoint Problem — The failure that arises when a trial's biomarker surrogate diverges from the clinical endpoint it stands in for — because the intervention acts through off-pathway mechanisms the surrogate cannot see — so individual-level correlation does not license an intervention-level claim.
• Therapeutic Duplication — The medication-safety failure where uncoordinated prescribers each place a defensible order that lands on the same pharmacologic target, so additive exposure overruns the therapeutic window — a harm that lives in the set of orders, not in any single one.
• Watchful Waiting — A clinical plan to defer a considered treatment while observing the condition and revisiting the decision if its course changes.